Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
Kymera Therapeutics, Inc. (KYMR) had Operating Cash Flow per Share of $-2.76 for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$2.87M |
|
$-86.98M |
|
-- |
|
$2.87M |
|
$100.77M |
|
$-97.89M |
|
$10.91M |
|
$-86.98M |
|
$-86.98M |
|
$-86.98M |
|
$-86.98M |
|
$-86.98M |
|
$-86.98M |
|
$-97.89M |
|
$-97.91M |
|
84.49M |
|
84.49M |
|
$-0.98 |
|
$-0.98 |
|
| Balance Sheet Financials | |
$871.21M |
|
$43.17M |
|
$871.60M |
|
$1.74B |
|
$83.21M |
|
$1.46M |
|
$79.94M |
|
$163.15M |
|
$1.58B |
|
$1.58B |
|
$1.58B |
|
81.32M |
|
| Cash Flow Statement Financials | |
$-232.89M |
|
$-521.06M |
|
$990.71M |
|
$126.05M |
|
$362.81M |
|
$236.76M |
|
$59.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.47 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
100.00% |
|
-3409.79% |
|
-3409.79% |
|
-- |
|
-3029.64% |
|
-3029.64% |
|
$-234.34M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-5.51% |
|
-5.51% |
|
-4.99% |
|
-5.50% |
|
$19.42 |
|
$-2.77 |
|
|
Operating Cash Flow per Share |
$-2.76 |